Suggested remit: To appraise the clinical and cost effectiveness of doxecitine–doxribtimine within its marketing authorisation for treating thymidine kinase 2 deficiency in people of any age.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- HST Standard
- ID number:
- 6484
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 August 2025 | Awaiting development. Following consideration by NICE's Prioritisation Board, the evaluation for doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484] has been routed to the Highly Specialised Technologies (HST) evaluation programme. Please note that the HST checklist will publish on the NICE website when the Invitation to Participate (ITP) is issued for the evaluation. Additionally, the timelines for the evaluation have been revised slightly. The evaluation will now begin in mid-August 2025 when we will write to you about how you can get involved. Submissions will be due in mid-October 2025. The first committee meeting will be held on 19 March 2026. For any queries relating to the evaluation, please contact [email protected]. |
| 15 April 2025 - 16 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6484 |
| 16 April 2025 | Referral |
| 15 April 2025 | In progress. Scoping commencing |
| 12 December 2024 | Referral |
| 08 November 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 19 August 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual